ALG13-Congenital Disorder of Glycosylation (ALG13-CDG) : Updated clinical and molecular review and clinical management guidelines
(2024) In Molecular Genetics and Metabolism 142(2).- Abstract
ALG13-Congenital Disorder of Glycosylation (CDG), is a rare X-linked CDG caused by pathogenic variants in ALG13 (OMIM 300776) that affects the N-linked glycosylation pathway. Affected individuals present with a predominantly neurological manifestation during infancy. Epileptic spasms are a common presenting symptom of ALG13-CDG. Other common phenotypes include developmental delay, seizures, intellectual disability, microcephaly, and hypotonia. Current management of ALG13-CDG is targeted to address patients’ symptoms. To date, less than 100 individuals have been reported with ALG13-CDG. In this article, an international group of experts in CDG reviewed all reported individuals affected with ALG13-CDG and suggested diagnostic and... (More)
ALG13-Congenital Disorder of Glycosylation (CDG), is a rare X-linked CDG caused by pathogenic variants in ALG13 (OMIM 300776) that affects the N-linked glycosylation pathway. Affected individuals present with a predominantly neurological manifestation during infancy. Epileptic spasms are a common presenting symptom of ALG13-CDG. Other common phenotypes include developmental delay, seizures, intellectual disability, microcephaly, and hypotonia. Current management of ALG13-CDG is targeted to address patients’ symptoms. To date, less than 100 individuals have been reported with ALG13-CDG. In this article, an international group of experts in CDG reviewed all reported individuals affected with ALG13-CDG and suggested diagnostic and management guidelines for ALG13-CDG. The guidelines are based on the best available data and expert opinion. Neurological symptoms dominate the phenotype of ALG13-CDG where epileptic spasm is confirmed to be the most common presenting symptom of ALG13-CDG in association with hypotonia and developmental delay. We propose that ACTH/prednisolone treatment should be trialed first, followed by vigabatrin, however ketogenic diet has been shown to have promising results in ALG13-CDG. In order to optimize medical management, we also suggest early cardiac, gastrointestinal, skeletal, and behavioral assessments in affected patients.
(Less)
- author
- organization
- publishing date
- 2024-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ALG13-CDG, Congenital disorders of glycosylation, Epileptic spasm, Seizure disorder, X-linked CDG
- in
- Molecular Genetics and Metabolism
- volume
- 142
- issue
- 2
- article number
- 108472
- publisher
- Elsevier
- external identifiers
-
- pmid:38703411
- scopus:85192097204
- ISSN
- 1096-7192
- DOI
- 10.1016/j.ymgme.2024.108472
- language
- English
- LU publication?
- yes
- id
- c3636bd3-3f9a-4251-91a0-189434ece38a
- date added to LUP
- 2024-05-20 12:48:17
- date last changed
- 2024-06-17 14:24:24
@article{c3636bd3-3f9a-4251-91a0-189434ece38a, abstract = {{<p>ALG13-Congenital Disorder of Glycosylation (CDG), is a rare X-linked CDG caused by pathogenic variants in ALG13 (OMIM 300776) that affects the N-linked glycosylation pathway. Affected individuals present with a predominantly neurological manifestation during infancy. Epileptic spasms are a common presenting symptom of ALG13-CDG. Other common phenotypes include developmental delay, seizures, intellectual disability, microcephaly, and hypotonia. Current management of ALG13-CDG is targeted to address patients’ symptoms. To date, less than 100 individuals have been reported with ALG13-CDG. In this article, an international group of experts in CDG reviewed all reported individuals affected with ALG13-CDG and suggested diagnostic and management guidelines for ALG13-CDG. The guidelines are based on the best available data and expert opinion. Neurological symptoms dominate the phenotype of ALG13-CDG where epileptic spasm is confirmed to be the most common presenting symptom of ALG13-CDG in association with hypotonia and developmental delay. We propose that ACTH/prednisolone treatment should be trialed first, followed by vigabatrin, however ketogenic diet has been shown to have promising results in ALG13-CDG. In order to optimize medical management, we also suggest early cardiac, gastrointestinal, skeletal, and behavioral assessments in affected patients.</p>}}, author = {{Shah, Rameen and Eklund, Erik A. and Radenkovic, Silvia and Sadek, Mustafa and Shammas, Ibrahim and Verberkmoes, Sanne and Ng, Bobby G. and Freeze, Hudson H. and Edmondson, Andrew C. and He, Miao and Kozicz, Tamas and Altassan, Ruqaiah and Morava, Eva}}, issn = {{1096-7192}}, keywords = {{ALG13-CDG; Congenital disorders of glycosylation; Epileptic spasm; Seizure disorder; X-linked CDG}}, language = {{eng}}, number = {{2}}, publisher = {{Elsevier}}, series = {{Molecular Genetics and Metabolism}}, title = {{ALG13-Congenital Disorder of Glycosylation (ALG13-CDG) : Updated clinical and molecular review and clinical management guidelines}}, url = {{http://dx.doi.org/10.1016/j.ymgme.2024.108472}}, doi = {{10.1016/j.ymgme.2024.108472}}, volume = {{142}}, year = {{2024}}, }